keyword
MENU ▼
Read by QxMD icon Read
search

CBR

keyword
https://www.readbyqxmd.com/read/28713800/strategies-for-meaningful-engagement-between-community-based-health-researchers-and-first-nations-participants
#1
Jaime Cidro, Marion Maar, Sabrina Peressini, Robert J Schroth, John Broughton, Lisa Jamieson, Herenia P Lawrence
The Baby Teeth Talk Study (BTT) is a partnership-based research project looking at interventions to prevent early childhood caries (ECC) in First Nations populations in Canada. Community-based researchers (CBRs) conducted preventive and behavioral interventions that targeted expectant mothers and their newborns, over a 3-year period. The work of the CBRs requires a great deal of training and skills to administer the interventions. It also requires a broad set of strategies to meaningfully engage participants to make health-promoting changes in their behavior to prevent ECC in their children...
2017: Frontiers in Public Health
https://www.readbyqxmd.com/read/28705409/clinical-benefit-and-risk-of-death-with-endocrine-therapy-in-ovarian-cancer-a-comprehensive-review-and-meta-analysis
#2
Laura Paleari, Sara Gandini, Nicoletta Provinciali, Matteo Puntoni, Nicoletta Colombo, Andrea DeCensi
BACKGROUND: Steroid hormones promote epithelial ovarian cancer (EOC) growth and their receptor expression is associated with disease outcome. Hormone therapy is frequently used in pretreated EOC, but the magnitude of activity overall and by specific agents or tumor characteristics is unknown. METHODS: Clinical Benefit Rates (CBR) and deaths from clinical trials of endocrine agents were meta-analyzed. Summary estimates of CBR (SCBR) and Odd Ratio for death (SOR) were calculated according with type of drug, ER and PgR status, platinum resistance, line of therapy, tumor grade and tamoxifen dose...
July 10, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28689667/is-hormonal-therapy-effective-in-advanced-endometrial-cancer-a-systematic-review-and-meta-analysis
#3
REVIEW
Josee-Lyne Ethier, Danielle N Desautels, Eitan Amir, Helen MacKay
BACKGROUND: Hormonal therapy (HT) is used commonly in the treatment of advanced endometrial cancer (EC). However, a 2010 Cochrane Review did not show a survival benefit for HT. Here, we quantify its effects and explore the influence of clinico-pathologic factors and hormone receptor (HR) status on overall response rates (ORR). METHODS: A systematic search of electronic databases identified publications of HT in advanced EC. Data from individual studies reporting ORR, median progression-free (PFS) or overall survival (OS) were weighted by individual study sample size and pooled in a meta-analysis...
July 6, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28687486/red-emitting-chimeric-firefly-luciferase-for-in%C3%A2-vivo-imaging-in-low-atp-cellular-environments
#4
Bruce R Branchini, Tara L Southworth, Danielle M Fontaine, Dawn Kohrt, Franceine S Welcome, Catherine M Florentine, Emma R Henricks, Demetria B DeBartolo, Elisa Michelini, Luca Cevenini, Aldo Roda, Martha J Grossel
Beetle luciferases have been adapted for live cell imaging where bioluminescence is dependent on the cellular availability of ATP, O2, and added luciferin. Previous Photinus pyralis red-emitting variants with high Km values for ATP have performed disappointingly in live cells despite having much higher relative specific activities than enzymes like Click Beetle Red (CBR). We engineered a luciferase variant PLR3 having a Km value for ATP similar to CBR and ∼2.6-fold higher specific activity. The red-emitting PLR3 was ∼2...
July 4, 2017: Analytical Biochemistry
https://www.readbyqxmd.com/read/28685075/combination-of-irinotecan-and-platinum-for-platinum-resistant-or-refractory-recurrent-ovarian-cancers-a-preliminary-case-series
#5
Takashi Shibutani, Masashi Takano, Morikazu Miyamoto, Tomoyuki Yoshikawa, Tadashi Aoyama, Hiroaki Soyama, Junko Hirata, Ayako Suzuki, Hidenori Sasa, Kenichi Furuya
Non-platinum single agents are usually used for patients with platinum-resistant recurrent ovarian cancers (ROC). However, the efficacy of these drugs is limited. The aim of the present study was to evaluate the efficacy and adverse events (AE) of combination therapy with irinotecan and platinum (CPT-Pt) for ROC. A total of 28 platinum-resistant or refractory patients with ROC treated with CPT-Pt at the National Defense Medical College Hospital institution between 2002 and 2012 were identified. All patients received taxane and carboplatin (TC) as a first-line treatment and relapsed within 6 months after completion of TC, or progressed during TC therapy...
July 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28679771/neratinib-efficacy-and-circulating-tumor-dna-detection-of-her2-mutations-in-her2-non-amplified-metastatic-breast-cancer
#6
Cynthia X Ma, Ron Bose, Feng Gao, Rachel A Freedman, Melinda L Telli, Gretchen Kimmick, Eric P Winer, Michael J Naughton, Matthew P Goetz, Christy Russell, Debu Tripathy, Melody Cobleigh, Andres Forero, Timothy J Pluard, Carey K Anders, Polly Niravath, Shana Thomas, Jill Anderson, Caroline Bumb, Kimberly C Banks, Richard B Lanman, Richard Bryce, Alshad S Lalani, John D Pfeifer, Daniel F Hayes, Mark D Pegram, Kimberly Blackwell, Phillipe L Bedard, Hussam Al-Kateb, Matthew J Ellis
Based on promising preclinical data, we conducted a single arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined  as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2(mut) non-amplified metastatic breast cancer (MBC).  Secondary endpoints included progression-free survival (PFS), toxicity, and circulating tumor DNA (ctDNA) HER2(mut) detection.  <p>Experimental Methods:  Tumor tissue positive for HER2(mut) was required for eligibility.  Neratinib was administered 240mg daily with prophylactic loperamide...
July 5, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28679770/therapy-of-small-cell-lung-cancer-sclc-with-a-topoisomerase-i-inhibiting-antibody-drug-conjugate-adc-targeting-trop-2-sacituzumab-govitecan
#7
Jhanelle E Gray, Rebecca S Heist, Alexander N Starodub, D Ross Camidge, Ebenezer A Kio, Gregory A Masters, W Thomas Purcell, Michael J Guarino, Jamal Misleh, Charles J Schneider, Bryan J Schneider, Allyson Ocean, Tirrell Johnson, Leena Gandhi, Kevin Kalinsky, Ronald Scheff, Wells A Messersmith, Serengulam V Govindan, Pius P Maliakal, Boyd Mudenda, William A Wegener, Robert M Sharkey, David M Goldenberg
Purpose: We evaluated a Trop-2-targeting antibody conjugated with SN-38 in metastatic small-cell lung cancer (mSCLC) patients. <p>Experimental Design: Sacituzumab govitecan was studied in patients with pretreated (median, 2; range, 1-7) mSCLC who received either 8 or 10 mg/kg i.v. on days 1 and 8 of 21-day cycles. The primary endpoints were safety and objective response rate (ORR); duration of response, progression-free survival (PFS), and overall survival (OS) were secondary endpoints.</p> <p>Results: Sixty percent of patients showed tumor shrinkage from baseline CTs...
July 5, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28674764/a-pilot-study-of-cabergoline-for-the-treatment-of-metastatic-breast-cancer
#8
Ricardo Costa, C A Santa-Maria, D M Scholtens, S Jain, L Flaum, W J Gradishar, C V Clevenger, V G Kaklamani
PURPOSE: The prolactin (PRL) receptor is over-expressed in breast cancer, and pre-clinical data indicate that it contributes to breast oncogenesis. Cabergoline is a potent dopamine receptor agonist of D2 receptors and has a direct inhibitory effect on pituitary PRL secretion. METHODS: A phase II study of cabergoline in patients with metastatic breast cancer was conducted. The primary end point of the study was to determine the clinical benefit rate (CBR) at 2 months...
July 3, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28666422/the-role-of-hormonal-therapy-in-patients-with-relapsed-high-grade-ovarian-carcinoma-a-retrospective-series-of-tamoxifen-and-letrozole
#9
Angela George, Jennifer McLachlan, Nina Tunariu, Chiara Della Pepa, Cristina Migali, Martin Gore, Stan Kaye, Susana Banerjee
BACKGROUND: Hormonal therapy is used as a treatment option in high-grade ovarian carcinoma (HGOC), but the role and choice of treatment remains unclear. Agents used include tamoxifen and aromatase inhibitors. Our aim was to evaluate the efficacy of tamoxifen (T) and letrozole (L) in HGOC in clinical practice and investigate factors influencing clinical outcome. METHODS: A retrospective review of patients with relapsed HGOC treated with either tamoxifen or letrozole at the Royal Marsden Hospital between 2007 and 2012 was performed...
June 30, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28655715/incretin-secretion-in-humans-is-under-the-influence-of-cannabinoid-receptors
#10
Chee W Chia, Olga D Carlson, David D Liu, Isabel González-Mariscal, Sara Santa-Cruz Calvo, Josephine M Egan
The mechanisms regulating incretin secretion are not fully known. Human obesity is associated with altered incretin secretion and elevated endocannabinoid levels. Since cannabinoid receptors (CBRs) are expressed on incretin-secreting cells in rodents, we hypothesized that endocannabinoids are involved in the regulation of incretin secretion. We compared plasma glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) responses during oral glucose tolerance test (OGTT) in twenty lean and twenty obese participants from the Baltimore Longitudinal Study of Aging (BLSA)...
June 27, 2017: American Journal of Physiology. Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28651804/efficacy-and-safety-of-trabectedin-or-dacarbazine-in-patients-with-advanced-uterine-leiomyosarcoma-after-failure-of-anthracycline-based-chemotherapy-subgroup-analysis-of-a-phase-3-randomized-clinical-trial
#11
Martee L Hensley, Shreyaskumar R Patel, Margaret von Mehren, Kristen Ganjoo, Robin L Jones, Arthur Staddon, Daniel Rushing, Mohammed Milhem, Bradley Monk, George Wang, Sharon McCarthy, Roland E Knoblauch, Trilok V Parekh, Robert G Maki, George D Demetri
OBJECTIVE: Trabectedin demonstrated significantly improved disease control in leiomyosarcoma and liposarcoma patients in a global phase 3 trial (NCT01343277). A post hoc analysis was conducted to assess the efficacy and safety of trabectedin or dacarbazine in women with uterine leiomyosarcoma (uLMS), the largest subgroup of enrolled patients (40%). METHODS: Of 577 patients randomized 2:1 to receive trabectedin 1.5mg/m(2) by 24-hour IV infusion or dacarbazine 1g/m(2) by 20-120-minute IV infusion once every three weeks, 232 had uLMS (trabectedin: 144; dacarbazine: 88)...
June 23, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28612226/iris-study-a-phase-ii-study-of-the-steroid-sulfatase-inhibitor-irosustat-when-added-to-an-aromatase-inhibitor-in-er-positive-breast-cancer-patients
#12
Carlo Palmieri, Rob C Stein, Xinxue Liu, Emma Hudson, Hanna Nicholas, Hironobu Sasano, Fouzia Guestini, Chris Holcombe, Sophie Barrett, Laura Kenny, Sadie Reed, Adrian Lim, Larry Hayward, Sacha Howell, R Charles Coombes
PURPOSE: Irosustat is a first-generation, orally active, irreversible steroid sulfatase inhibitor. We performed a multicentre, open label phase II trial of the addition of Irosustat to a first-line aromatase inhibitor (AI) in patients with advanced BC to evaluate the safety of the combination and to test the hypothesis that the addition of Irosustat to AI may further suppress estradiol levels and result in clinical benefit. EXPERIMENTAL DESIGN: Postmenopausal women with ER-positive locally advanced or metastatic breast cancer who had derived clinical benefit from a first-line AI and who subsequently progressed were enrolled...
June 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28586749/everolimus-induced-pneumonitis-associates-with-favourable-outcome-in-patients-with-metastatic-renal-cell-carcinoma
#13
P Penttilä, F Donskov, J Rautiola, K Peltola, M Laukka, P Bono
BACKGROUND: Mammalian target of rapamycin inhibitors may induce pneumonitis. We analysed the association of pneumonitis with outcomes in everolimus treated metastatic renal cell carcinoma (mRCC) patients. PATIENTS AND METHODS: Eighty-five mRCC patients received everolimus at Helsinki University Hospital (cohort A). Computed tomography (CT) verified pneumonitis was correlated with outcome using Kaplan-Meier, Cox regression and logistic regression. An independent cohort of 148 everolimus treated mRCC patients (cohort B) at Aarhus University Hospital was assessed for validation...
August 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28575102/development-of-indicators-for-monitoring-community-based-rehabilitation
#14
Catherine Mason, Joerg Weber, Seryan Atasoy, Carla Sabariego, Alarcos Cieza
BACKGROUND: Community-Based Rehabilitation (CBR) is a multi-sectoral approach working to equalize opportunities and include people with disability in all aspects of community life. Reliable and internationally comparable data needed to monitor and evaluate CBR are scarce, partially due to the absence of standardized indicators. The objective of this manuscript is to describe the collaborative development process which led to the World Health Organization's (WHO) recently launched set of standardized CBR outcome indicators...
2017: PloS One
https://www.readbyqxmd.com/read/28545610/a-case-based-reasoning-system-based-on-weighted-heterogeneous-value-distance-metric-for-breast-cancer-diagnosis
#15
Dongxiao Gu, Changyong Liang, Huimin Zhao
OBJECTIVE: We present the implementation and application of a case-based reasoning (CBR) system for breast cancer related diagnoses. By retrieving similar cases in a breast cancer decision support system, oncologists can obtain powerful information or knowledge, complementing their own experiential knowledge, in their medical decision making. METHODS: We observed two problems in applying standard CBR to this context: the abundance of different types of attributes and the difficulty in eliciting appropriate attribute weights from human experts...
March 2017: Artificial Intelligence in Medicine
https://www.readbyqxmd.com/read/28527352/a-cbr-framework-with-gradient-boosting-based-feature-selection-for-lung-cancer-subtype-classification
#16
Juan Ramos-González, Daniel López-Sánchez, Jose A Castellanos-Garzón, Juan F de Paz, Juan M Corchado
Molecular subtype classification represents a challenging field in lung cancer diagnosis. Although different methods have been proposed for biomarker selection, efficient discrimination between adenocarcinoma and squamous cell carcinoma in clinical practice presents several difficulties, especially when the latter is poorly differentiated. This is an area of growing importance, since certain treatments and other medical decisions are based on molecular and histological features. An urgent need exists for a system and a set of biomarkers that provide an accurate diagnosis...
July 1, 2017: Computers in Biology and Medicine
https://www.readbyqxmd.com/read/28521525/babbling-in-children-with-neurodevelopmental-disability-and-validity-of-a-simplified-way-of-measuring-canonical-babbling-ratio
#17
Anna Nyman, Anette Lohmander
Babbling is an important precursor to speech, but has not yet been thoroughly investigated in children with neurodevelopmental disabilities. Canonical babbling ratio (CBR) is a commonly used but time-consuming measure for quantifying babbling. The aim of this study was twofold: to validate a simplified version of the CBR (CBR(UTTER)), and to use this measure to determine if early precursors to speech and language development could be detected in children with different neurodevelopmental disabilities. Two different data sets were used...
May 19, 2017: Clinical Linguistics & Phonetics
https://www.readbyqxmd.com/read/28520849/beta-blockers-and-improved-progression-free-survival-in-patients-with-advanced-her2-negative-breast-cancer-a-retrospective-analysis-of-the-rose-trio-012-study
#18
G Spera, R Fresco, H Fung, J R B Dyck, E Pituskin, I Paterson, J R Mackey
Background: Recent retrospective studies suggest that beta-adrenergic blocking drugs (BB) are associated with improved outcomes in people with a range of cancers. Although limited and discordant data suggest that BB may increase overall survival (OS) of patients with localized breast cancer (BC), there is no information on the effects of BB in women with advanced BC. Patients and Methods: To explore the association between BB use and BC outcomes, we retrospectively reviewed the ROSE/TRIO-012, a double-blinded, multinational phase III trial that randomized 1,144 patients with HER2-negative advanced BC to first-line docetaxel in combination with ramucirumab or placebo...
May 18, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28507235/assessing-the-strength-of-cardiac-and-sympathetic-baroreflex-controls-via-transfer-entropy-during-orthostatic-challenge
#19
Alberto Porta, Andrea Marchi, Vlasta Bari, Beatrice De Maria, Murray Esler, Elisabeth Lambert, Mathias Baumert
The study assesses the strength of the causal relation along baroreflex (BR) in humans during an incremental postural challenge soliciting the BR. Both cardiac BR (cBR) and sympathetic BR (sBR) were characterized via BR sequence approaches from spontaneous fluctuations of heart period (HP), systolic arterial pressure (SAP), diastolic arterial pressure (DAP) and muscle sympathetic nerve activity (MSNA). A model-based transfer entropy method was applied to quantify the strength of the coupling from SAP to HP and from DAP to MSNA...
June 28, 2017: Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences
https://www.readbyqxmd.com/read/28488183/palbociclib-a-review-in-hr-positive-her2-negative-advanced-or-metastatic-breast-cancer
#20
REVIEW
Esther S Kim, Lesley J Scott
Oral palbociclib (Ibrance®) is a first-in-class, highly selective inhibitor of cyclin-dependent kinases 4 and 6 (i.e. a CDK4/6 inhibitor). It is indicated for the treatment of women with HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine-based therapy, and in combination with fulvestrant (with or without a luteinizing hormone-releasing hormone agonist) in those previously treated with endocrine therapy. In clinical trials, palbociclib in combination with letrozole as initial endocrine-based therapy in postmenopausal women (PALOMA-1 and PALOMA-2), or in combination with fulvestrant in pre-, peri-, or postmenopausal women with disease progression after endocrine therapy (PALOMA-3), significantly prolonged progression-free survival (PFS) and improved clinical benefit response (CBR) rates...
May 9, 2017: Targeted Oncology
keyword
keyword
83265
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"